Table of Contents
Letter to the Editor
  • Myeloid Sarcoma: The Clinician's Point of View, M. Malagola, M. Tiribelli, D. Russo, A. Candoni, G. Visani, and A. Isidori
    Leukemia Research and Treatment
    Letter to the Editor (2 pages), Article ID 410291, Volume 2011 (2011)
    Published 27 April 2011
Leukemia Research and Treatment
Volume 2011, Article ID 523168, 4 pages
Research Article

Myeloid Sarcoma: Clinicopathologic, Cytogenetic, and Outcome Analysis of 21 Adult Patients

1Medical Oncology Department, King Hussein Cancer Center, Al-Jubeiha, Amman 11941, Jordan
2Pathology Department, King Hussein Cancer Center, Al-Jubeiha, Amman 11941, Jordan

Received 10 November 2010; Accepted 7 December 2010

Academic Editor: Alessandro Isidori

Copyright © 2011 Hani Al-Khateeb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Myeloid sarcoma (MS) is a neoplasm of immature granulocytes, monocytes, or both involving any extramedullary site. Twenty one patients with MS at diagnosis who were treated at King Hussein Cancer Center in Jordan were included in this retrospective study with a male to female ratio of 2 : 1. The most common site was the reticuloendothelial system. The most common morphology subtype was M2 (38%) and the most frequent chromosomal abnormality was trisomy 8. Twenty patients received induction chemotherapy; only 14 (70%) achieved complete remission. Median survival time was 24.7 months for the whole group and 58.6 months for patients who underwent allogenic bone marrow transplant. This paper showed that MS has frequent M2 morphology, carries chromosomal aberrations other than t(8;21), and requires aggressive therapy as a front line approach.